MX2021002665A - Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas. - Google Patents

Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.

Info

Publication number
MX2021002665A
MX2021002665A MX2021002665A MX2021002665A MX2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A
Authority
MX
Mexico
Prior art keywords
annulene
oxyphenyl
pyrrolidin
dichlorophenyl
benzo
Prior art date
Application number
MX2021002665A
Other languages
English (en)
Inventor
Joël Malpart
Montes José Ruiz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021002665A publication Critical patent/MX2021002665A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente memoria se proporcionan sales novedosas de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7H-benzo[7]anulen-2-carboxilato de metilo, concretamente la sal de oxalato (ver Fórmula) y la sal de dibenzoiltartrato. (ver Fórmulas).
MX2021002665A 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas. MX2021002665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306177 2018-09-07
PCT/EP2019/073823 WO2020049150A1 (en) 2018-09-07 2019-09-06 Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof

Publications (1)

Publication Number Publication Date
MX2021002665A true MX2021002665A (es) 2021-07-16

Family

ID=63637829

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021002665A MX2021002665A (es) 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.
MX2021002666A MX2021002666A (es) 2018-09-07 2019-09-06 Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002666A MX2021002666A (es) 2018-09-07 2019-09-06 Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.

Country Status (18)

Country Link
US (2) US20210188771A1 (es)
EP (2) EP3847157B1 (es)
JP (2) JP7398436B2 (es)
KR (2) KR20210057032A (es)
CN (2) CN112638869A (es)
AR (2) AR116300A1 (es)
AU (2) AU2019335542A1 (es)
BR (2) BR112021003061A2 (es)
CA (2) CA3111359A1 (es)
DK (2) DK3847156T3 (es)
ES (2) ES2923412T3 (es)
HU (2) HUE059527T2 (es)
IL (2) IL281191B (es)
MX (2) MX2021002665A (es)
SG (2) SG11202102059YA (es)
TW (2) TWI803692B (es)
WO (2) WO2020049153A1 (es)
ZA (2) ZA202101006B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
ES2923412T3 (es) 2018-09-07 2022-09-27 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
WO2022001971A1 (zh) 2020-06-28 2022-01-06 南京明德新药研发有限公司 并环吲唑类化合物
AU2021366217A1 (en) 2020-10-19 2023-06-22 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022084298A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
WO2023198903A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n‑propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198905A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198901A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2023198879A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198904A1 (en) * 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286893T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
JP2005528320A (ja) 2001-08-11 2005-09-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 選択的なエストロゲン受容体モジュレーター
JP4554219B2 (ja) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション エストロゲン受容体調節剤
JP4500689B2 (ja) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
MX2007000036A (es) 2004-06-25 2007-05-18 Johnson & Johnson Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
WO2009101634A2 (en) 2008-02-13 2009-08-20 Lupin Limited A novel process for the preparation of eszopiclone
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US20120130129A1 (en) 2010-11-16 2012-05-24 Baylor University Efficient Method for Preparing Functionalized Benzosuberenes
WO2012084711A1 (en) 2010-12-24 2012-06-28 Msd Oss B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CA2861939A1 (en) 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
DK3033086T3 (da) 2013-08-14 2022-01-03 Novartis Ag Kombinationsterapi til behandling af cancer
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JP2016540767A (ja) 2013-12-06 2016-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 局所進行性又は転移性エストロゲン受容体陽性乳がんの治療のためのエストロゲン受容体調節因子
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
US9980947B2 (en) 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
IL297369B1 (en) 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc RAD for use in a method to treat mutant estrogen receptor positive breast cancer or mutant estrogen receptor positive ovarian cancer
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
PL3416962T3 (pl) 2016-02-15 2021-11-22 Sanofi Pochodne 6,7-dihydro-5H-benzo[7]annulenu jako modulatory receptorów estrogenowych
SG11201903908PA (en) 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
ES2923412T3 (es) 2018-09-07 2022-09-27 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
AU2019379179A1 (en) 2018-11-16 2021-06-10 Arqule, Inc. Pharmaceutical combination for treatment of cancer
SG11202111979SA (en) 2019-05-09 2021-11-29 Sanofi Sa 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients

Also Published As

Publication number Publication date
CA3111359A1 (en) 2020-03-12
JP2021536468A (ja) 2021-12-27
ZA202101006B (en) 2022-08-31
AR116299A1 (es) 2021-04-21
DK3847156T3 (da) 2022-07-25
IL281191B (en) 2022-07-01
US20210188771A1 (en) 2021-06-24
TW202026280A (zh) 2020-07-16
IL281191A (en) 2021-04-29
HUE059527T2 (hu) 2022-11-28
TWI803692B (zh) 2023-06-01
AU2019335542A1 (en) 2021-04-01
US20210188772A1 (en) 2021-06-24
IL281196B (en) 2022-10-01
HUE059362T2 (hu) 2022-11-28
EP3847156A1 (en) 2021-07-14
ZA202101079B (en) 2022-09-28
AU2019336532A1 (en) 2021-04-01
WO2020049150A1 (en) 2020-03-12
TW202024032A (zh) 2020-07-01
IL281196A (en) 2021-04-29
SG11202102057SA (en) 2021-03-30
JP2021536471A (ja) 2021-12-27
MX2021002666A (es) 2021-07-16
DK3847157T3 (da) 2022-08-08
EP3847157B1 (en) 2022-05-18
IL281196B2 (en) 2023-02-01
JP7398436B2 (ja) 2023-12-14
US11713296B2 (en) 2023-08-01
BR112021003061A2 (pt) 2021-05-11
CN112638869A (zh) 2021-04-09
WO2020049153A1 (en) 2020-03-12
CN112638870A (zh) 2021-04-09
BR112021003440A2 (pt) 2021-05-18
EP3847157A1 (en) 2021-07-14
JP7413363B2 (ja) 2024-01-15
CA3111466A1 (en) 2020-03-12
ES2924738T3 (es) 2022-10-10
EP3847156B1 (en) 2022-05-04
SG11202102059YA (en) 2021-03-30
KR20210057031A (ko) 2021-05-20
KR20210057032A (ko) 2021-05-20
AR116300A1 (es) 2021-04-21
ES2923412T3 (es) 2022-09-27

Similar Documents

Publication Publication Date Title
MX2021002665A (es) Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.
EP4306111A3 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CY1122075T1 (el) 1-((3s,4r)-4-(3-φθοροφαινυλ)-1-(2-μεθοξυαιθυλ)πυρρολιδιν-3-υλ)-3-(4-μεθυλ-(2-μεθυλοπυριμιδιν-5-υλ)-1 -φαινυλ-1 η-πυραζολ-5-υλ)ουρια ή φαρμακευτικα αποδεκτο αλας αυτης, που επιδεικνυει αναστολη κινασης trka
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
MX2020008367A (es) Formas cristalinas novedosas.
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EP3950681A3 (en) Salts and solid forms of the compound (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
MX2020005818A (es) Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
DK1599450T3 (da) Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister
EA201790290A1 (ru) Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
MX2021012849A (es) Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak.
MX2021003453A (es) Derivados de ciclopropilmetilamida activos como pesticidas.
WO2019133629A8 (en) Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
PE20070713A1 (es) 4-amino-5-cloro-n-{[1-(tetrahidro-2h-piran-4-ilmetil)-4-piperidinil]metil}-1-benzofuran-7-carboxamida en el tratamiento de alzheimer
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
AR111255A1 (es) Derivados de 4-piperidin-n-(pirimidin-4-il)croman-7-sulfonamidas inhibidores de canales de sodio
EA201892261A1 (ru) Гетероциклические амиды, пригодные в качестве модуляторов белков
EP3848037A4 (en) SOLID PHARMACEUTICAL COMPOSITION WITH 1,3,5-TRIAZINE DERIVATE OR A SALT THEREOF
MA56071A (fr) Procédés de préparation de 3-bromo-1-(3-chloropyridine-2-yl)-1h-pyrazole-5-carboxylate d'éthyle
EA201990640A1 (ru) Таблеточные композиции
WO2020041683A3 (en) Acid addition salts of apomorphine, pharmaceutical compositions containing the same, and methods of using the same
MX2021003607A (es) Compuestos insecticidas.
EA202092787A1 (ru) Синтез типифарниба
DK1708987T3 (da) L-(-)-moprolol-L-(+)-tartrat